Successful treatment with baricitinib in a patient with refractory cutaneous dermatomyositis

Rheumatology (Oxford). 2020 Dec 1;59(12):e125-e127. doi: 10.1093/rheumatology/keaa184.

Authors

Paolo Delvino¹, Alice Bartoletti¹, Sara Monti^{1

2}, Alessandro Biglia¹, Carlomaurizio Montecucco¹, Mauro Carducci³, Giorgio Ripamonti³, Lorenzo Cavagna¹

Affiliations

¹ Rheumatology Department, IRCCS Policlinico S. Matteo Foundation, University of Pavia.
² Rheumatology Department, IRCCS Policlinico S. Matteo Foundation, University of Pavia, Pavia.
³ Division of Internal Medicine, COQ, Madonna del Popolo Hospital, Omegna, Italy.

PMID: 32353871
DOI: 10.1093/rheumatology/keaa184

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Azetidines / therapeutic use*
Dermatomyositis / drug therapy*
Female
Humans
Middle Aged
Purines / therapeutic use*
Pyrazoles / therapeutic use*
Remission Induction
Skin Diseases / drug therapy*
Sulfonamides / therapeutic use*

Substances

Azetidines
Purines
Pyrazoles
Sulfonamides
baricitinib